Table 3.

Neutropenia Duration, Febrile Episodes, and Hospitalizations for All Patients

Filgrastim + Cladribine Cladribine Alone PValue
Days of filgrastim administration (including priming) 
 Median (range)  10 (5-52)  N/A  
Days to ANC >1.0 × 109/L  
 Median (range)  9 (8-41) 22 (7-64)  <10−53-150 
No. of febrile patients (%)  19/35 (54%)  47/105 (45%)  .43  
No. of febrile days (all patients)  
 Median (range)  1 (0-11) 3 (0-41)  .21  
No. of febrile days (only febrile patients)  
 Median (range)  3 (1-11)  6 (1-41)  .17 
No. of patients with nadir ANC  
 0 to 0.199 × 109/L  8   48   .0083-150 
 0.2 to 0.499 × 109/L  7   23   
 0.5 to 0.999 × 109/L  14   14  
 ≥1.0 × 109/L  6   20   
No. of patients at onset of fever with ANC (%)  
 0 to 0.199 × 109/L  4 (21)  12 (26)  .258 
 0.2 to 0.499 × 109/L  2 (11)  14 (30) 
 0.5 to 0.999 × 109/L  5 (26)  10 (21) 
 ≥1.0 × 109/L  8 (42)  11 (23)  
 (19 total febrile patients)  (47 total febrile patients) 
Filgrastim + Cladribine Cladribine Alone PValue
Days of filgrastim administration (including priming) 
 Median (range)  10 (5-52)  N/A  
Days to ANC >1.0 × 109/L  
 Median (range)  9 (8-41) 22 (7-64)  <10−53-150 
No. of febrile patients (%)  19/35 (54%)  47/105 (45%)  .43  
No. of febrile days (all patients)  
 Median (range)  1 (0-11) 3 (0-41)  .21  
No. of febrile days (only febrile patients)  
 Median (range)  3 (1-11)  6 (1-41)  .17 
No. of patients with nadir ANC  
 0 to 0.199 × 109/L  8   48   .0083-150 
 0.2 to 0.499 × 109/L  7   23   
 0.5 to 0.999 × 109/L  14   14  
 ≥1.0 × 109/L  6   20   
No. of patients at onset of fever with ANC (%)  
 0 to 0.199 × 109/L  4 (21)  12 (26)  .258 
 0.2 to 0.499 × 109/L  2 (11)  14 (30) 
 0.5 to 0.999 × 109/L  5 (26)  10 (21) 
 ≥1.0 × 109/L  8 (42)  11 (23)  
 (19 total febrile patients)  (47 total febrile patients) 
Mean Median Range Mean Median RangeP Value
Fever duration according to ANC at onset (d)  
 0 to 0.199 × 109/L  6.3  6.5 1-11  11.7  6  1-41  .544  
 0.2 to 0.499 × 109/L  3  3  3  5.5  5 1-14  .177  
 0.5 to 0.999 × 109/L  3.6 2  1-10  5.9  5.5  1-13  .221 
 ≥1.0 × 109/L  3.8  1  1-11  6.9 7  1-17  .137  
No. of days with ANC (until day +37) 
 0 to 0.199 × 109/L  2.2  0  0-36  4.2 0  0-33  .02943-150 
 0.2 to 0.499 × 109/L 1.3  0  0-7  5.2  4  0-28  .00083-150 
 0.5 to 0.999 × 109/L  2.6  2  0-9  8.0  7 0-36  .00043-150 
 ≥1.0 × 109/L  30.9  34 0-37  19.6  18  0.37 .<10−43-150 
Mean Median Range Mean Median RangeP Value
Fever duration according to ANC at onset (d)  
 0 to 0.199 × 109/L  6.3  6.5 1-11  11.7  6  1-41  .544  
 0.2 to 0.499 × 109/L  3  3  3  5.5  5 1-14  .177  
 0.5 to 0.999 × 109/L  3.6 2  1-10  5.9  5.5  1-13  .221 
 ≥1.0 × 109/L  3.8  1  1-11  6.9 7  1-17  .137  
No. of days with ANC (until day +37) 
 0 to 0.199 × 109/L  2.2  0  0-36  4.2 0  0-33  .02943-150 
 0.2 to 0.499 × 109/L 1.3  0  0-7  5.2  4  0-28  .00083-150 
 0.5 to 0.999 × 109/L  2.6  2  0-9  8.0  7 0-36  .00043-150 
 ≥1.0 × 109/L  30.9  34 0-37  19.6  18  0.37 .<10−43-150 
No. of patients admitted (%)  11/35 (31%)   45/105 (43%)  .31  
No. of hospital days  
 Median (range)   9 (1-35)  7 (3-41)  .44  
No. of IV antibiotic days (hospitalized patients)  
 Median (range)  7 (1-35)   5 (2-31)  .96  
No. of oral antibiotic days  
 Median (range)   10 (1-28)  10 (1-31)  .45  
  (11 patients)  (25 patients)  
No. of patients admitted (%)  11/35 (31%)   45/105 (43%)  .31  
No. of hospital days  
 Median (range)   9 (1-35)  7 (3-41)  .44  
No. of IV antibiotic days (hospitalized patients)  
 Median (range)  7 (1-35)   5 (2-31)  .96  
No. of oral antibiotic days  
 Median (range)   10 (1-28)  10 (1-31)  .45  
  (11 patients)  (25 patients)  
F3-150

Nominally significant at α level .05 (P < .05).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal